Future oncology最新文献_第2页

Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma by line of therapy. 套细胞淋巴瘤患者的现实世界特征、治疗模式和治疗结果。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-03 DOI: 10.1080/14796694.2025.2565829

Helmneh M Sineshaw, Claire Bai, Enrico de Nigris, Jennifer Prescott, Uzor Ogbu, Christina M Zettler, Laura L Fernandes, Ching-Kun Wang

{"title":"Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma by line of therapy.","authors":"Helmneh M Sineshaw, Claire Bai, Enrico de Nigris, Jennifer Prescott, Uzor Ogbu, Christina M Zettler, Laura L Fernandes, Ching-Kun Wang","doi":"10.1080/14796694.2025.2565829","DOIUrl":"https://doi.org/10.1080/14796694.2025.2565829","url":null,"abstract":"Background: Approvals of Bruton's tyrosine kinase inhibitors (BTKis) and other novel agents have changed the Mantle Cell Lymphoma (MCL) treatment paradigm, necessitating assessment of contemporaneous, real-world (rw) treatment and outcomes by line of therapy (LOT).Methods: Patients diagnosed with MCL on or after 1 January 2012 who initiated first-line (1 L) treatment in the COTA database were eligible, excluding those with concurrent primaries, history of hematologic malignancies, clinical trial participation, or missing/imprecise key dates. Rw time to next treatment (rwTTNT) and overall survival (rwOS) were evaluated using the Kaplan-Meier method from LOT start (index).Results: Of 499 patients, most were ≥ 50 years (94.8%), male (71.5%), treated in the community (58.7%), and diagnosed with stage III/IV disease (91.2%). The most common 1 L regimen was bendamustine+rituximab (BR)±R maintenance (12.6%/23.0%, respectively). Fifty (10.0%) patients received 1 L autologous stem cell transplant. One hundred and seventy-three patients (34.7%) received 2 L, of which 72 (41.6% of 2 L) received 3 L, of which 29 (40.3% of 3 L) received 4 L +. BTKi monotherapy was the most frequently administered therapy in 2 L (26.0%).Median rwTTNT and rwOS from 1 L to 4 L were 36.8-3.2 and 86.2-8.7 months, respectively.Conclusions: Outcomes of patients who received 2 L+ for MCL remain poor, highlighting unmet need in the contemporary treatment paradigm.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":2.6,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Finding the right tool for the specific task: navigating RWE tools and checklists. 为特定任务找到正确的工具：导航RWE工具和检查表。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-01 DOI: 10.1080/14796694.2025.2552098

Richard Willke, Paul Cottu, Andrew Briggs, Uwe Siebert, Connie Chen, Beata Korytowsky, Julien Heidt, Meghan Renfrow, Kate Lovett, Adam Brufsky

{"title":"Finding the right tool for the specific task: navigating RWE tools and checklists.","authors":"Richard Willke, Paul Cottu, Andrew Briggs, Uwe Siebert, Connie Chen, Beata Korytowsky, Julien Heidt, Meghan Renfrow, Kate Lovett, Adam Brufsky","doi":"10.1080/14796694.2025.2552098","DOIUrl":"10.1080/14796694.2025.2552098","url":null,"abstract":"Real-world evidence (RWE) is increasingly used to support product approvals and label expansions, as well as clinical and payer decision-making. Various tools (e.g. frameworks, checklists) have been developed to help inform and assess the robustness and quality of real-world study design and reporting. This targeted review provides a practical guide for leveraging these tools to increase awareness and utility for decision-makers. A pre-defined search strategy was applied to identify articles from PubMed. Articles published from 1 January 2020, through 4 October 2024 were included and reviewed to identify relevant tools aimed at assessing RWE study planning, reporting, or quality assessment. Key information regarding each was extracted and summarized including strengths, limitations, and included domains. 119 articles were initially identified, of which 15 were included after screening, referencing a total of 17 tools. These 17 tools varied in format and structure, ranging from detailed guidelines and templates to checklists and questionnaires. Utility and application of the tools identified in this targeted review vary across the evaluation of study planning, reporting, and quality. Selection of the appropriate tool depends on several factors including intended purpose of the tool, intended real-world study design, and the availability of study documentation.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3075-3089"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study. 鲁索利替尼在日本骨髓纤维化患者中的长期安全性和有效性：一项观察性研究。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-08-29 DOI: 10.1080/14796694.2025.2550924

Yusuke Aruga, Wataru Hongo, Weizhe Lu

{"title":"Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study.","authors":"Yusuke Aruga, Wataru Hongo, Weizhe Lu","doi":"10.1080/14796694.2025.2550924","DOIUrl":"10.1080/14796694.2025.2550924","url":null,"abstract":"Aim: To evaluate the safety and effectiveness of ruxolitinib in patients with myelofibrosis (MF) in Japan.Methods: A multicenter, observational study of patients who received ruxolitinib for MF from July 2014.Results: Of 892 patients (mean age: 70 years, 45.9% primary MF, ruxolitinib treatment median duration, 541.0 days), 67.7% had adverse drug reactions (ADRs) and 31.5% had serious ADRs. The most frequent ADRs were anemia and decreased platelet count. Incidences of ADRs by time of onset were 57.7%, 20.3%, 14.4%, 11.1%, 11.3%, 9.0%, and 1.8% from the treatment initiation to Day 182, and every 6 months thereafter until Day 1,093 or later, respectively. ADRs of special interest included myelosuppression (46.8%), infections (17.6%), hepatic impairment (13.5%), hemorrhagic events (10.2%), cardiac failure (2.5%), interstitial lung disease (1.5%), malignancy (1.4%) and tuberculosis (0.5%). Incidences of common ADRs were similar between patients with hepatic or renal impairment and patients without hepatic or renal impairment. At 6 months, spleen responses and symptom improvement were observed in 26.2% and 52.0% of patients, respectively. Median overall survival was not reached.Conclusion: In a real-world setting in Japan, ruxolitinib demonstrated a reasonable degree of effectiveness with no new safety concerns. Results were similar to those from clinical trials.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3017-3026"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Paclitaxel-based strategy as first-line therapy for advanced breast cancer: a model-based economic evaluation for China. 紫杉醇作为晚期乳腺癌一线治疗策略：中国基于模型的经济评估。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-08-26 DOI: 10.1080/14796694.2025.2550832

Ji-Sheng Chen, Jia Hu, Meng-Ting Li

{"title":"Paclitaxel-based strategy as first-line therapy for advanced breast cancer: a model-based economic evaluation for China.","authors":"Ji-Sheng Chen, Jia Hu, Meng-Ting Li","doi":"10.1080/14796694.2025.2550832","DOIUrl":"10.1080/14796694.2025.2550832","url":null,"abstract":"Aim: The limited number of cost-utility studies of breast cancer conducted in China makes comparisons among different paclitaxel-based strategies difficult. To provide such data, a cost-utility analysis comparing albumin-bound formulation (nab)-paclitaxel (ABPTX), paclitaxel polymer micelles (PTXPM), and paclitaxel (PTX) for advanced breast cancer was performed.Methods: Tree Age Pro 2011 software was used to simulate a Markov model to perform a health economic evaluation. Patient-related data for this study were obtained from large multicenter Phase III clinical trial studies. Quality-adjusted life years (QALYs) and the incremental cost-effectiveness ratio (ICER) were considered as primary outcomes.Results: The model results showed that the 60-cycle mortality rate was 98.3% in the ABPTX group and 99.7% in the PTXPM group. Cost-utility analysis calculated that ABPTX had an increased life expectancy of 0.183 QALYs compared with patients receiving PTXPM, with an incremental cost of $4,914.747, resulting in an ICER value of $26,846.310 per QALY. When the willingness-to-pay (WTP) threshold was increased to approximately $30,000 per QALY, PTXPM had a 50% probability of being cost-effective compared with ABPTX.Conclusion: At the WTP threshold of $37,721.52/QALY in China, ABPTX is more cost-effective than PTXPM under equivalent efficacy and safety, from the Chinese healthcare perspective.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3005-3015"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review. 实体恶性肿瘤患者间质性肺病的流行病学和病因学：系统的文献综述。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-01 DOI: 10.1080/14796694.2025.2550928

Egbert F Smit, Simon M Collin, Manoj Prahladan, Flavia Lujan, Emma Drane, Emily Kaiser, Ambar Khan, Pierfranco Conte

{"title":"Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review.","authors":"Egbert F Smit, Simon M Collin, Manoj Prahladan, Flavia Lujan, Emma Drane, Emily Kaiser, Ambar Khan, Pierfranco Conte","doi":"10.1080/14796694.2025.2550928","DOIUrl":"10.1080/14796694.2025.2550928","url":null,"abstract":"Background: Interstitial lung disease (ILD) can occur in patients with cancer. ILD can be caused by anti-cancer treatments (drug-induced [DI] ILD), but also by opportunistic infection, and non-drug-related etiologies. This systematic literature review (SLR) investigated the epidemiology and etiology of non-DI ILD and DI ILD management and outcomes in patients with solid cancers.Methods: Databases were searched to August 2023 using terms for ILD and solid cancers. Relevant congresses held 2021-2023 and SLR bibliographies were hand-searched. Records were screened by two independent reviewers. Inclusion criteria comprised ILD epidemiology outcomes, ILD clinical management, and survival outcomes.Results: Of 4,519 unique records screened, 55 full texts were included (six from supplementary sources) and 37 were prioritized for extraction. Studies were frequently retrospective cohort studies in Japan (n = 21). Patients mostly had lung cancers (n = 32) and received immune checkpoint inhibitors (n = 24). Reporting of non-DI ILD was limited and associated with radiation therapy (n = 4) or surgery (n = 1). Most studies reported DI ILD outcomes only (n = 31).Conclusion: The limited evidence of non-DI ILD indicates that prompt intervention to manage ILD until other ILD etiologies have been ruled out remains key to preventing progression of both cancer and ILD.Protocol registration http://www.crd.york.ac.uk/prospero identifier: CRD42023463573.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3063-3073"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy. TROPHY-U-01研究（队列2）的简单语言总结：转移性尿路上皮癌患者不能接受顺铂化疗，免疫治疗后使用sacituzumab govitecan。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-01 DOI: 10.1080/14796694.2025.2548757

Petros Grivas, Scott T Tagawa, Rohit K Jain, Manojkumar Bupathi, Arjun Balar, Arash Rezazadeh Kalebasty, Saby George, Phillip Palmbos, Luke Nordquist, Daniel P Petrylak, Nancy Davis, Cora N Sternberg, Neeraj Agarwal, Chandler Park, Julia Tonelli, Huafeng Zhou, Rick Bangs, Yohann Loriot

引用次数: 0

Plain language summary of a systematic review of palbociclib treatment for advanced/ metastatic breast cancer in older patients. 帕博西尼治疗老年晚期/转移性乳腺癌的系统综述。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-15 DOI: 10.1080/14796694.2025.2550930

Etienne Brain, Connie Chen, Sofia Simon, Vinay Pasupuleti, Kathleen Vieira Pfitzer, Karen A Gelmon

引用次数: 0

Disease management landscape in patients with mantle cell lymphoma in Japan: a real-world study. 日本套细胞淋巴瘤患者的疾病管理情况：一项真实世界的研究。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-07 DOI: 10.1080/14796694.2025.2555165

Shinya Rai, Yoshinori Tanizawa, Tomoko Terasawa, Masaomi Tajimi, Ryuichi Ideue, Helen Burlison, Neil Milloy, Amber Simpson, Kaisa-Leena Taipale, Min-Hua Jen, Grace Segall, Benjamin Goebel, Amit Kiran

{"title":"Disease management landscape in patients with mantle cell lymphoma in Japan: a real-world study.","authors":"Shinya Rai, Yoshinori Tanizawa, Tomoko Terasawa, Masaomi Tajimi, Ryuichi Ideue, Helen Burlison, Neil Milloy, Amber Simpson, Kaisa-Leena Taipale, Min-Hua Jen, Grace Segall, Benjamin Goebel, Amit Kiran","doi":"10.1080/14796694.2025.2555165","DOIUrl":"10.1080/14796694.2025.2555165","url":null,"abstract":"Aim: The objective of this study was to describe the disease management landscape for patients with mantle cell lymphoma (MCL) in Japan.Methods: We conducted a cross-sectional survey with retrospective data capture of physicians and their consulting patients between March and December 2022. Physicians completed patient record forms in a 1:2 ratio: one patient receiving first-line (1 L) treatment and two patients with relapsed/refractory disease, one of whom must have received and discontinued a Bruton's tyrosine kinase inhibitor (BTKi).Results: Sixty-seven patients were included - most were male (74.6%) and diagnosed with classical MCL (76.1%), with a mean age of 69.4 years and median time since MCL diagnosis of 18.0 months. The most common initial symptom was painless swelling in the neck, armpit, stomach, or groin (72%). Overall, patients had a \"complete response\" to 1 L (32/67 [47.8%]) therapy and \"partial response\" to 2 L (24/45 [53.3%]) therapy. Side effects were less commonly reported with BTKi than with chemotherapy. The most important physician-perceived treatment goal was to \"minimize impact on patient's daily life\" or \"tumor response\" for patients receiving BTKi or chemotherapy, respectively.Conclusion: Patients' disease was generally well-managed by their physicians; however, improvements in efficacy, safety, and quality of life are still needed.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3051-3062"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic and therapeutic appropriateness in different stages of esophageal/GEJ cancers. The FICOG project. 食管癌/食管贲门癌不同分期诊断和治疗的适宜性。FICOG项目。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-09 DOI: 10.1080/14796694.2025.2551482

Carmine Pinto, Carlo Castoro, Ferdinando De Vita, Alberto Gianluigi Luporini, Evaristo Maiello, Renzo Mazzarotto, Aldo Scarpa, Riccardo Caccialanza, Angela Damato

{"title":"Diagnostic and therapeutic appropriateness in different stages of esophageal/GEJ cancers. The FICOG project.","authors":"Carmine Pinto, Carlo Castoro, Ferdinando De Vita, Alberto Gianluigi Luporini, Evaristo Maiello, Renzo Mazzarotto, Aldo Scarpa, Riccardo Caccialanza, Angela Damato","doi":"10.1080/14796694.2025.2551482","DOIUrl":"10.1080/14796694.2025.2551482","url":null,"abstract":"Background: Esophageal cancer is a rare neoplasm, with more than 0.6 million new cases and 0.54 million deaths worldwide in 2020. The distal third of the esophagus and the gastroesophageal junction (GEJ) are mostly involved sites. The diagnosis and therapeutic management of early, locally advanced, and metastatic disease continue to present uncertainties, as existing guidelines may not fully address all clinical questions in these areas.Methods: A group of Italian Experts produced recommendations for early, locally advanced, and metastatic disease management using the RAND/UCLA Appropriateness Method. Statements were generated by a systematic revision of the literature and voted on twice by a panel of 29 expert physicians; the second vote took place during a meeting of the panelists.Results: Several topics covered diagnosis, staging, treatment, and early, localized, and metastatic disease management. Recommendations were stated.Conclusions: Interventions considered appropriate to improve compliance and outcomes of esophageal/GEJ cancer patients were identified.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3027-3041"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12492973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary. talquetamab治疗复发/难治性多发性骨髓瘤的副作用管理：一个简单的语言总结。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-15 DOI: 10.1080/14796694.2025.2555170

Ajai Chari, Samantha Shenoy, Sandy Kruyswijk, Brandi Hilder, Lisa O'Rourke, Niels W C J van de Donk

引用次数: 0